Drugs / DC/AML fusion cells
DC/AML fusion cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03679650 | Oct 2018 → Mar 2026 overdue | acute myeloid leukemia | Beth Israel Deaconess Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC/AML fusion cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03679650 ↗ |
| Known as | DC/AML vaccine | “This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML).” NCT03679650 ↗ |
| Known as | Dendritic Cell/AML Fusion vaccine | “This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML).” NCT03679650 ↗ |
| Modality | Vaccine | “a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine)” NCT03679650 ↗ |